Systemic and local ex vivo gene therapy of the skeleton

Patent metadata

Field	Value
Publication number	US-9789162-B2
Application number	US-201514932826-A
Country	US
Kind code	B2
Filing date	Nov 4, 2015
Priority date	Nov 5, 2014
Publication date	Oct 17, 2017
Grant date	Oct 17, 2017

Abstract

Methods are disclosed herein for increasing bone mass and strength or bone fracture healing in a subject. The methods include administering to the subject a therapeutically effective amount of multipotent stem cells, wherein each multipotent stem cell is transformed with a recombinant nucleic acid molecule comprising a heterologous promoter operably linked to a nucleic acid encoding platelet derived growth factor (PDGF) B, and wherein the multipotent stem cells express a sufficient amount of PDGFB to increase bone mass and strength or bone fracture healing. A lentiviral vector also is disclosed that includes a phosphoglycerate kinase-1 (PGK) promoter operably linked to a nucleic acid encoding PDGFB.

First claim

We claim:

1. A method of increasing bone mass and strength in a subject, comprising:
administering to the subject a therapeutically effective amount of hematopoietic stem cells transformed with a recombinant nucleic acid molecule encoding platelet derived growth factor (PDGF)B operably linked to a phosphoglycerate kinase-1 (PGK) promoter, wherein the transformed hematopoietic stem cells express PDGFB within the vascular niches in the marrow cavity; thereby increasing bone mass and strength in the subject.

2. The method of claim 1 , wherein the subject is human, and wherein a serum concentration of PDGFB is 0.1 to 30 ng/ml at five weeks following administration of the hematopoietic stem cells.

3. The method of claim 1 , wherein increasing bone mass and strength comprises an increase in trabecular number, an increase in trabecular connectivity, an increase in de novo trabecular bone formation, an increase in endosteal bone formation, and/or a decrease in bone porosity.

4. The method of claim 1 , wherein the hematopoietic stem cell is transformed with a vector comprising the recombinant nucleic acid molecule.

5. The method of claim 4 , wherein the vector is a retroviral vector, an adenoviral vector, or an adeno-associated vector (AAV).

6. The method of claim 5 , wherein the retroviral vector is a lentiviral vector.

7. The method of claim 1 , wherein the recombinant nucleic acid molecule is integrated into a safe harbor locus in a genome of the hematopoietic stem cell.

8. The method of claim 7 , wherein the recombinant nucleic acid molecule is integrated into the safe harbor locus using CRISPR gene editing technology.

9. The method of claim 4 , wherein the vector further comprises a suicide gene.

10. The method of claim 9 , wherein the suicide gene is HSV thymidine kinase (HSV-TK).

11. The method of claim 1 , wherein the subject has a bone disease or disorder that affects bone strength.

12. The method of claim 11 , wherein the subject has a metabolic bone disease.

13. The method of claim 11 , wherein the subject has osteoporosis, osteogenic imperfecta, or avascular necrosis.

14. The method of claim 1 , wherein the subject has cancer.

15. The method of claim 14 , wherein the subject is preconditioned using total or local body irradiation, or chemically induced myeloablation, prior to administration of the hematopoietic stem cells.

16. The method of claim 1 , wherein the hematopoietic stem cells produce about 1 to about 10 ng per 10 6 cells of PDGFB in 24 hours.

17. The method of claim 1 , wherein the hematopoietic stem cells produce about 2 to about 6 ng per 10 6 cells of PDGFB in 24 hours.

18. The method of claim 1 , wherein the hematopoietic stem cells are autologous.

19. The method of claim 1 , wherein the hematopoietic stem cells are Sca1 positive hematopoietic stem cells.

20. The method of claim 1 , wherein the subject is preconditioned prior to administration of the hematopoietic stem cells.

21. The method of claim 20 , wherein the subject is preconditioned using total or local body irradiation prior to administration of the hematopoietic stem cells.

22. The method of claim 20 , wherein the subject is preconditioned using chemically induced myeloablation prior to administration of the hematopoietic stem cells.

23. The method of claim 1 , wherein the hematopoietic stem cells are administered intravenously.

24. The method of claim 5 , wherein the retroviral vector is a Molony leukemia virus (MLV) vector.

25. The method of claim 1 , wherein the hematopoietic stem cells express an amount of PDGFB sufficient to increase bone strength.

Assignees

• Us Veterans Affairs
• Univ Loma Linda
• The Us Dept Of Veteran Affairs

Inventors

• Baylink David
• Lau Kin-Hing William
• Chen Wanqiu
• Zhang xiao-bing

Classifications

• C12N2800/00

  Nucleic acids vectors · CPC title

• C12N2740/15071

  Demonstrated in vivo effect · CPC title

• C12N2740/15043

  viral genome or elements thereof as genetic vector · CPC title

• C12N2510/00

  Genetically modified cells · CPC title

• C12N2501/135

  Platelet-derived growth factor [PDGF] · CPC title